While we wait for NASH da­ta, Gen­fit re­ports pos­i­tive elafi­bra­nor da­ta in PBC pa­tients

As a late-stage da­ta show­down from NASH drug de­vel­op­ers Gilead $GILD, In­ter­cept $ICPT and France’s Gen­fit (Eu­roNext: $GN­FT) looms, the Lille-based drug de­vel­op­er on Thurs­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER